RU2011121388A - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS - Google Patents

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS Download PDF

Info

Publication number
RU2011121388A
RU2011121388A RU2011121388/15A RU2011121388A RU2011121388A RU 2011121388 A RU2011121388 A RU 2011121388A RU 2011121388/15 A RU2011121388/15 A RU 2011121388/15A RU 2011121388 A RU2011121388 A RU 2011121388A RU 2011121388 A RU2011121388 A RU 2011121388A
Authority
RU
Russia
Prior art keywords
rosuvastatin
composition according
calcium
amount
pharmaceutical composition
Prior art date
Application number
RU2011121388/15A
Other languages
Russian (ru)
Other versions
RU2508109C2 (en
Inventor
Светлана Витальевна Емшанова
Николай Иванович Юрченко
Ольга Юрьевна Лащёва
Ксения Анатольевна Фадина
Наталья Викторовна Гончарова
Original Assignee
Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") filed Critical Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")
Priority to RU2011121388/15A priority Critical patent/RU2508109C2/en
Publication of RU2011121388A publication Critical patent/RU2011121388A/en
Application granted granted Critical
Publication of RU2508109C2 publication Critical patent/RU2508109C2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

1. Гиполипидемическая фармацевтическая композиция в виде твердой лекарственной формы, включающая в качестве действующего вещества розувастатин кальция в терапевтически эффективном количестве, и вспомогательные вещества - наполнитель, дезинтегрант, глидант и лубрикант, при этом она не содержит неорганическую соль с поливалентным катионом.2. Композиция по п.1, которая включает в качестве наполнителя модифицированную лактозу.3. Композиция по п.2, которая включает розувастатин кальция в аморфной форме.4. Композиция по п.3, которая выполнена в виде таблетки, покрытой оболочкой.5. Композиция по п.5, которая содержит в единичной дозе розувастатин кальция в количестве 10 мг (в пересчете на розувастатин).6. Композиция по п.5, которая содержит в единичной дозе розувастатин кальция в количестве приблизительно 20 мг (в пересчете на розувастатин).1. A lipid-lowering pharmaceutical composition in the form of a solid dosage form, comprising as active ingredient calcium rosuvastatin in a therapeutically effective amount, and excipients - filler, disintegrant, glidant and lubricant, while it does not contain an inorganic salt with a polyvalent cation. 2. A composition according to claim 1, which comprises modified lactose as a filler. A composition according to claim 2, which comprises calcium rosuvastatin in an amorphous form. The composition according to claim 3, which is made in the form of a coated tablet. The composition according to claim 5, which contains in a single dose of rosuvastatin calcium in an amount of 10 mg (in terms of rosuvastatin). The composition according to claim 5, which contains in a single dose of rosuvastatin calcium in an amount of approximately 20 mg (in terms of rosuvastatin).

Claims (6)

1. Гиполипидемическая фармацевтическая композиция в виде твердой лекарственной формы, включающая в качестве действующего вещества розувастатин кальция в терапевтически эффективном количестве, и вспомогательные вещества - наполнитель, дезинтегрант, глидант и лубрикант, при этом она не содержит неорганическую соль с поливалентным катионом.1. A lipid-lowering pharmaceutical composition in the form of a solid dosage form, comprising as active ingredient rosuvastatin calcium in a therapeutically effective amount, and excipients - filler, disintegrant, glidant and lubricant, while it does not contain an inorganic salt with a polyvalent cation. 2. Композиция по п.1, которая включает в качестве наполнителя модифицированную лактозу.2. The composition according to claim 1, which includes a modified lactose as a filler. 3. Композиция по п.2, которая включает розувастатин кальция в аморфной форме.3. The composition according to claim 2, which includes calcium rosuvastatin in an amorphous form. 4. Композиция по п.3, которая выполнена в виде таблетки, покрытой оболочкой.4. The composition according to claim 3, which is made in the form of a coated tablet. 5. Композиция по п.5, которая содержит в единичной дозе розувастатин кальция в количестве 10 мг (в пересчете на розувастатин).5. The composition according to claim 5, which contains in a single dose of rosuvastatin calcium in an amount of 10 mg (in terms of rosuvastatin). 6. Композиция по п.5, которая содержит в единичной дозе розувастатин кальция в количестве приблизительно 20 мг (в пересчете на розувастатин). 6. The composition according to claim 5, which contains in a single dose of rosuvastatin calcium in an amount of approximately 20 mg (in terms of rosuvastatin).
RU2011121388/15A 2011-05-27 2011-05-27 Pharmaceutical composition for treating lipid storage disease RU2508109C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2011121388/15A RU2508109C2 (en) 2011-05-27 2011-05-27 Pharmaceutical composition for treating lipid storage disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011121388/15A RU2508109C2 (en) 2011-05-27 2011-05-27 Pharmaceutical composition for treating lipid storage disease

Publications (2)

Publication Number Publication Date
RU2011121388A true RU2011121388A (en) 2012-12-10
RU2508109C2 RU2508109C2 (en) 2014-02-27

Family

ID=49255389

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011121388/15A RU2508109C2 (en) 2011-05-27 2011-05-27 Pharmaceutical composition for treating lipid storage disease

Country Status (1)

Country Link
RU (1) RU2508109C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649811C2 (en) * 2013-12-18 2018-04-04 Алвоген Кореа Ко, Лтд. PHARMACEUTICAL COMBINATION PREPARATION CONTAINING THE INHIBITOR OF HMG-CoA REDUCTASE AND INHIBITOR OF CHOLESTEROL ABSORPTION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649811C2 (en) * 2013-12-18 2018-04-04 Алвоген Кореа Ко, Лтд. PHARMACEUTICAL COMBINATION PREPARATION CONTAINING THE INHIBITOR OF HMG-CoA REDUCTASE AND INHIBITOR OF CHOLESTEROL ABSORPTION

Also Published As

Publication number Publication date
RU2508109C2 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
HRP20210343T1 (en) Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
RU2014149181A (en) PYRAZOLE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
JP2012193216A5 (en)
PE20140389A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOFIBROSIS
MX2021010046A (en) A new therapeutical composition containing apomorphine as active ingredient.
BR112014014795A2 (en) immediate release multi-unit pellet system
RU2015109566A (en) NEW EXTRACTS FROM CYNARA SCOLYMUS, COFFEA spp. AND OLEA EUROPAEA FOR THE TREATMENT OF A METABOLIC SYNDROME
EA201590142A1 (en) PHARMACEUTICAL MEDICINE FORMS CONTAINING 5-CHLOR-N - ({(5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) PHENYL] -1,3-OXAZOZOLIDIN-5-IL} METH) -2-TIOFEN-CARBOXAMID
MX2019005160A (en) Pharmaceutical formulation.
RU2011121388A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIPID METABOLIC DISORDERS
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
JP2012041314A5 (en)
RU2009145804A (en) AXOMADOL FOR TREATING PAIN FROM ARTHROSIS
HRP20211309T1 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
RU2014148062A (en) INJECTION PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN AND TRAMADOL
RU2013105211A (en) APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS
RU2013127794A (en) PHARMACEUTICAL COMBINATION AND COMPOSITION FOR TREATING OBESITY AND ITS APPLICATION
MX2013008996A (en) Novel pharmaceutical system of biphasic delivery for treating pain and inflammation.
HRP20171930T1 (en) Diazonamide analogs
MX2018008443A (en) Pharmaceutical composition comprising nebivolol with improved dissolution rate.
RU2013127881A (en) APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment
BR112015030388A2 (en) pharmaceutical formulation
RU2012124232A (en) PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180528